To halt brain diseases, drugs take aim at protein traffic jams that kill neurons
Elie Dolgin • January 16, 2019
Compound that normalizes flow of proteins in cells will now be tested in a clinical trial for ALS
Continue reading at Science Magazine.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.